Myovant Sciences Ltd. Common Shares (MYOV): Price and Financial Metrics

Myovant Sciences Ltd. Common Shares (MYOV)

Today's Latest Price: $20.03 USD

0.12 (-0.60%)

Updated Jul 2 7:00pm

Add MYOV to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MYOV Daily Price Range
MYOV 52-Week Price Range

MYOV Stock Price Chart Technical Analysis Charts

MYOV Price/Volume Stats

Current price $20.03 52-week high $22.07
Prev. close $20.15 52-week low $4.14
Day low $19.83 Volume 569,348
Day high $20.44 Avg. volume 1,089,055
50-day MA $15.02 Dividend yield N/A
200-day MA $11.44 Market Cap 1.80B

Myovant Sciences Ltd. Common Shares (MYOV) Company Bio

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.

MYOV Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MYOV Latest Social Stream

Loading social stream, please wait...

View Full MYOV Social Stream

Latest MYOV News From Around the Web

Below are the latest news stories about Myovant Sciences Ltd that investors may wish to consider to help them evaluate MYOV as an investment opportunity.

Goldman Sachs: There’s an Opportunity Brewing in These 3 Stocks

The COVID-19 pandemic has decimated the U.S. economy, yet the stock market is alive and well. Against the backdrop of a recession, the market actually had its strongest quarter in over 20 years, with the S&P 500 notching its largest quarterly gain since the last quarter of 1998, surging 20%. As for the NASDAQ, it climbed 31% higher during the quarter, marking its best quarterly performance since Q4 1999.While certainly volatile, the quarter saw investors take an optimistic approach due to reopening efforts and unprecedented stimulus packages. That being said, going forward into Q3, plenty of uncertainty is lingering over Wall Street. So, how are investors supposed to lock in on compelling plays? The Street’s pros can provide some much-needed inspiration, namely those from investment fir...

Yahoo | July 1, 2020, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer

CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANGELES, Calif.; and BASEL, Switzerland, June 30, 2020 (GLOBE NEWSWIRE) --, Evidation Health, Movember, and Myovant Sciences (NYSE: MYOV) today announced the launch of Forward Momentum, a cross-sector coalition working on innovative projects to increase diversity in research and develop new digital resources for men with prostate cancer. Prostate cancer is the second most prevalent form of cancer and second leading cause of cancer death in men in the U.S. More than 3 million men have been diagnosed with prostate cancer in the U.S. and more than 33,000 deaths are expected in 2020, with Black men twice as likely to die from the disease.

Yahoo | June 30, 2020

The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dya...

Benzinga | June 24, 2020

Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up

Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.

Yahoo | June 24, 2020

Company News for Jun 24, 2020

Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.

Yahoo | June 24, 2020

Read More 'MYOV' Stories Here

MYOV Price Returns

1-mo 24.26%
3-mo 155.48%
6-mo 40.17%
1-year 130.49%
3-year 81.27%
5-year N/A
YTD 29.06%
2019 -5.42%
2018 29.83%
2017 1.61%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8921 seconds.